Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity

Kathleen A Ross,1 Hyelee Loyd,2 Wuwei Wu,2 Lucas Huntimer,3 Shaheen Ahmed,4 Anthony Sambol,5 Scott Broderick,6 Zachary Flickinger,2 Krishna Rajan,6 Tatiana Bronich,4 Surya Mallapragada,1 Michael J Wannemuehler,3 Susan Carpenter,2 Balaji Narasimhan1 1Chemical and Biological Engineering, Iowa State...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ross KA, Loyd H, Wu W, Huntimer L, Ahmed S, Sambol A, Broderick S, Flickinger Z, Rajan K, Bronich T, Mallapragada S, Wannemuehler MJ, Carpenter S, Narasimhan B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/1ff86ccb4d4c4334ad1bc7d428a0f3a2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1ff86ccb4d4c4334ad1bc7d428a0f3a2
record_format	dspace
spelling	oai:doaj.org-article:1ff86ccb4d4c4334ad1bc7d428a0f3a22021-12-02T07:43:45ZHemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity1178-2013https://doaj.org/article/1ff86ccb4d4c4334ad1bc7d428a0f3a22014-12-01T00:00:00Zhttp://www.dovepress.com/hemagglutinin-based-polyanhydride-nanovaccines-against-h5n1-influenza--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013 Kathleen A Ross,1 Hyelee Loyd,2 Wuwei Wu,2 Lucas Huntimer,3 Shaheen Ahmed,4 Anthony Sambol,5 Scott Broderick,6 Zachary Flickinger,2 Krishna Rajan,6 Tatiana Bronich,4 Surya Mallapragada,1 Michael J Wannemuehler,3 Susan Carpenter,2 Balaji Narasimhan1 1Chemical and Biological Engineering, Iowa State University, Ames, IA, USA; 2Animal Science, Iowa State University, Ames, IA, USA; 3Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, IA, USA; 4Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA; 5Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA; 6Materials Science and Engineering, Iowa State University, Ames, IA, USA Abstract: H5N1 avian influenza is a significant global concern with the potential to become the next pandemic threat. Recombinant subunit vaccines are an attractive alternative for pandemic vaccines compared to traditional vaccine technologies. In particular, polyanhydride nanoparticles encapsulating subunit proteins have been shown to enhance humoral and cell-mediated immunity and provide protection upon lethal challenge. In this work, a recombinant H5 hemagglutinin trimer (H53) was produced and encapsulated into polyanhydride nanoparticles. The studies performed indicated that the recombinant H53 antigen was a robust immunogen. Immunizing mice with H53 encapsulated into polyanhydride nanoparticles induced high neutralizing antibody titers and enhanced CD4+ T cell recall responses in mice. Finally, the H53-based polyanhydride nanovaccine induced protective immunity against a low-pathogenic H5N1 viral challenge. Informatics analyses indicated that mice receiving the nanovaccine formulations and subsequently challenged with virus were similar to naïve mice that were not challenged. The current studies provide a basis to further exploit the advantages of polyanhydride nanovaccines in pandemic scenarios. Keywords: polymer, nanoparticle, vaccine, subunit, neutralizing antibodyRoss KALoyd HWu WHuntimer LAhmed SSambol ABroderick SFlickinger ZRajan KBronich TMallapragada SWannemuehler MJCarpenter SNarasimhan BDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2015, Iss default, Pp 229-243 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Ross KA Loyd H Wu W Huntimer L Ahmed S Sambol A Broderick S Flickinger Z Rajan K Bronich T Mallapragada S Wannemuehler MJ Carpenter S Narasimhan B Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity
description	Kathleen A Ross,1 Hyelee Loyd,2 Wuwei Wu,2 Lucas Huntimer,3 Shaheen Ahmed,4 Anthony Sambol,5 Scott Broderick,6 Zachary Flickinger,2 Krishna Rajan,6 Tatiana Bronich,4 Surya Mallapragada,1 Michael J Wannemuehler,3 Susan Carpenter,2 Balaji Narasimhan1 1Chemical and Biological Engineering, Iowa State University, Ames, IA, USA; 2Animal Science, Iowa State University, Ames, IA, USA; 3Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, IA, USA; 4Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA; 5Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA; 6Materials Science and Engineering, Iowa State University, Ames, IA, USA Abstract: H5N1 avian influenza is a significant global concern with the potential to become the next pandemic threat. Recombinant subunit vaccines are an attractive alternative for pandemic vaccines compared to traditional vaccine technologies. In particular, polyanhydride nanoparticles encapsulating subunit proteins have been shown to enhance humoral and cell-mediated immunity and provide protection upon lethal challenge. In this work, a recombinant H5 hemagglutinin trimer (H53) was produced and encapsulated into polyanhydride nanoparticles. The studies performed indicated that the recombinant H53 antigen was a robust immunogen. Immunizing mice with H53 encapsulated into polyanhydride nanoparticles induced high neutralizing antibody titers and enhanced CD4+ T cell recall responses in mice. Finally, the H53-based polyanhydride nanovaccine induced protective immunity against a low-pathogenic H5N1 viral challenge. Informatics analyses indicated that mice receiving the nanovaccine formulations and subsequently challenged with virus were similar to naïve mice that were not challenged. The current studies provide a basis to further exploit the advantages of polyanhydride nanovaccines in pandemic scenarios. Keywords: polymer, nanoparticle, vaccine, subunit, neutralizing antibody
format	article
author	Ross KA Loyd H Wu W Huntimer L Ahmed S Sambol A Broderick S Flickinger Z Rajan K Bronich T Mallapragada S Wannemuehler MJ Carpenter S Narasimhan B
author_facet	Ross KA Loyd H Wu W Huntimer L Ahmed S Sambol A Broderick S Flickinger Z Rajan K Bronich T Mallapragada S Wannemuehler MJ Carpenter S Narasimhan B
author_sort	Ross KA
title	Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity
title_short	Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity
title_full	Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity
title_fullStr	Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity
title_full_unstemmed	Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity
title_sort	hemagglutinin-based polyanhydride nanovaccines against h5n1 influenza elicit protective virus neutralizing titers and cell-mediated immunity
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/1ff86ccb4d4c4334ad1bc7d428a0f3a2
work_keys_str_mv	AT rosska hemagglutininbasedpolyanhydridenanovaccinesagainsth5n1influenzaelicitprotectivevirusneutralizingtitersandcellmediatedimmunity AT loydh hemagglutininbasedpolyanhydridenanovaccinesagainsth5n1influenzaelicitprotectivevirusneutralizingtitersandcellmediatedimmunity AT wuw hemagglutininbasedpolyanhydridenanovaccinesagainsth5n1influenzaelicitprotectivevirusneutralizingtitersandcellmediatedimmunity AT huntimerl hemagglutininbasedpolyanhydridenanovaccinesagainsth5n1influenzaelicitprotectivevirusneutralizingtitersandcellmediatedimmunity AT ahmeds hemagglutininbasedpolyanhydridenanovaccinesagainsth5n1influenzaelicitprotectivevirusneutralizingtitersandcellmediatedimmunity AT sambola hemagglutininbasedpolyanhydridenanovaccinesagainsth5n1influenzaelicitprotectivevirusneutralizingtitersandcellmediatedimmunity AT brodericks hemagglutininbasedpolyanhydridenanovaccinesagainsth5n1influenzaelicitprotectivevirusneutralizingtitersandcellmediatedimmunity AT flickingerz hemagglutininbasedpolyanhydridenanovaccinesagainsth5n1influenzaelicitprotectivevirusneutralizingtitersandcellmediatedimmunity AT rajank hemagglutininbasedpolyanhydridenanovaccinesagainsth5n1influenzaelicitprotectivevirusneutralizingtitersandcellmediatedimmunity AT bronicht hemagglutininbasedpolyanhydridenanovaccinesagainsth5n1influenzaelicitprotectivevirusneutralizingtitersandcellmediatedimmunity AT mallapragadas hemagglutininbasedpolyanhydridenanovaccinesagainsth5n1influenzaelicitprotectivevirusneutralizingtitersandcellmediatedimmunity AT wannemuehlermj hemagglutininbasedpolyanhydridenanovaccinesagainsth5n1influenzaelicitprotectivevirusneutralizingtitersandcellmediatedimmunity AT carpenters hemagglutininbasedpolyanhydridenanovaccinesagainsth5n1influenzaelicitprotectivevirusneutralizingtitersandcellmediatedimmunity AT narasimhanb hemagglutininbasedpolyanhydridenanovaccinesagainsth5n1influenzaelicitprotectivevirusneutralizingtitersandcellmediatedimmunity
_version_	1718399206588153856

Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity

Ejemplares similares